Journal of the European Academy of Dermatology and Venereology
© European Academy of Dermatology and Venereology
Editor-in-Chief: Prof. Dr. med. Dr. phil. Johannes Ring, München, Germany
Impact Factor: 2.826
ISI Journal Citation Reports © Ranking: 2014: 11/63 (Dermatology)
Online ISSN: 1468-3083
Psoriasis White Paper
A framework for improving the quality of care for people with psoriasis
A European Expert Working Group for Healthcare in Psoriasis (EEWGHP) has found that people living with moderate to severe psoriasis are often undertreated1, and there is enormous variation across Europe in the quality of care that they receive.2,3 Early access to high-quality care – the right treatment, at the right time – is central to improving the overall treatment experience, and long-term outlook, for a person with psoriasis. However, the group found that there are currently many patients not benefiting from early access to high-quality care.
The Psoriasis White Paper ‘A framework for improving the quality of care for people with psoriasis’ is the outcome of the EEWGHP’s findings and discussions, and provides a framework for improving early access to high-quality care for people with psoriasis in Europe, through raised awareness and consistent management. Ultimately, it is hoped that this framework will help to raise treatment aspirations in psoriasis (of both healthcare professionals and people with psoriasis), thereby improving clinical outcomes and quality of life (QoL) for the 17 to 25 million4,5 people living with psoriasis in Europe.
For more information, please click here to view a short presentation on the Psoriasis White Paper.
Click here for a two-page summary document providing an overview of the recommendations set out in the Psoriasis White Paper.
You can show your support for the rights of people with psoriasis, and to call for the recommendations of the Psoriasis White Paper to be acted on. The Psoriasis Mandate is an online petition highlighting 5 key rights of people with psoriasis.
Click here to sign the Psoriasis Mandate and show your support for improved standards of care for each and every person living with psoriasis in Europe today.
The Psoriasis White Paper and the Psoriasis Mandate are supported by Janssen, more specifically Janssen Pharmaceutica NV, Belgium.
1. Mrowietz U, Kragballe K, Reich K et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res 2011; 303: 1–10.
2. Pathirana D, Ormerod AD, Saiag P et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Vene-reol 2009; 23: 1–70.
3. Augustin M, Krüger K, Radtke MA et al. Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter cross-sectional study in Germany. Dermatology 2008; 216: 366–372.
5. World Health Organisation. Available at: www.who.int/choice/demography/pop_death_rates/en/index.html. Last accessed August 2013.